Disease from chemo and radiation
[back] Chemo  [back] radiation

Whoever masterminded this chemo-torture deserves a monument in hell.----Dr. Hamer

[Long term risks. Hardly surprising, but they keep very quiet on this one, and this is on top of the pain and suffering endured during the treatment.  Chemotherapy can also cause sterility.  Non-toxic chemotherapy, such as Laetrile isn't allowed as: 1. it has no patent, so no profits, 2. it is nutritional medicine that treats causes not symptoms, which would bust Allopathy, and 3. it isn't toxic, see Covert genocide]

See citations: Toxicity citation (children)  Drug citations  Carmofur (HCFU) Chemo toxicity Cisplatin  Fluorouracil 5FU  Methotrexate  Tamoxifen
See: Daniel Hauser

[2009 may] Cancer risk for child survivors they were three times more likely to develop a new cancer than their contemporaries - and the risk remained even as people approached their seventies.

[2008] Chemotherapy can do more harm than good, study suggests About 300,000 patients now receive chemotherapy in the UK each year, a 60 per cent increase compared to 2004. ...... in a study of more than 600 cancer patients who died within 30 days of receiving treatment, chemotherapy probably caused or hastened death in 27 per cent of cases, the inquiry found.

[2006] Childhood cancer 'long-term risk' US scientists discovered they were more than three times as likely to suffer chronic health conditions compared with their cancer-free counterparts. And they were about eight times as likely to suffer a severe or life-threatening condition.  The cancer survivors, who had all been diagnosed with cancer between 1970 and 1986, were more vulnerable to second cancers, heart conditions, kidney disease, musculoskeletal problems, osteoporosis and sterility.

[NVIC 2006] Chemo has long-term impact on brain function, study finds   Experts estimate that at least 25 percent of chemotherapy patients are affected by symptoms of confusion, so-called chemo brain, and a recent study by the University of Minnesota reported an 82 percent rate.....Now that the brain damaging risks of chemotherapy are finally revealed, just like the brain damaging effects of anti-depressants, ADHD drugs and vaccines have been revealed, it is time to make it illegal for medical doctors to force medical treatment on U.S. citizens for any reason. There is no freedom more fundamental than the right to voluntarily choose what you are willing to risk your life or the life of your child for when making health care decisions.

[2004] "Cancer survivors face other battles"  31% of survivors described their health as fair or poor, compared with 18% of other people. Cancer survivors more often suffered from a litany of ills, including arthritis, back or neck problems, fractures, high blood pressure and breathing problems.

The adverse reactions to Taxol are well known. These are tabulated in the drug's prescribing information and can be readily found at the FDA Web site, www.fda.gov. Here are a few statistics, derived from a study of the single-use of Taxol in 812 breast cancer patients.
Neutropenia - 52 to 90 percent of patients, depending on the dose.
Leukopenia - 17 to 90 percent
Anemia - 16 to 78 percent
Infections - 30 percent
Hypersensitivity reactions - 41 percent
Hypotension - 12 percent
Abnormal ECGs - 23 percent
Peripheral neuropathy, any symptoms - 60 percent
Myalgia/arthralgia - 60 percent
Nausea and vomiting - 52 percent
Alopecia (hair loss) - 87 percent
Injection site reactions - 13 percent
Some of these problems, such as numbness and tingling in the hands and feet, persist for months and years following Taxol treatment. [2007] TAXOL DOES NOT HELP PREVENT RECURRENCE OF MOST COMMON BREAST CANCERS by Ralph Moss

"A study of over 10,000 patients shows clearly that chemo’s supposedly strong track record with Hodgkin’s disease (lymphoma) is actually a lie. Patients who underwent chemo were 14 times more likely to develop leukemia and 6 times more likely to develop cancers of the bones, joints, and soft tissues than those patients who did not undergo chemotherapy (NCI Journal 87:10)."—John Diamond

Children who are successfully treated for Hodgkin's disease are 18 times more likely later to develop secondary malignant tumours. Girls face a 35 per cent chance of developing breast cancer by the time they are 40----which is 75 times greater than the average. The risk of leukemia increased markedly four years after the ending of successful treatment, and reached a plateau after 14 years, but the risk of developing solid tumours remained high and approached 30 per cent at 30 years (New Eng J Med, March 21, 1996)

Quotes re Tamoxifen [See: Tamoxifen]
Uterine cancer is one of the possible side-effects of Tamoxifen. One study showed that 27 per cent of women taking Tamoxifen showed hyperplastic (unfavourable new growth) changes in their wombs within 15 months. Tamoxifen is carcinogenic and can cause an early menopause, osteoporosis, endometrial cancer, liver cancer and clotting disease. Taking 20 milligrams of Tamoxifen per day can increase the risk for developing endometrial cancer by up to five times. Clotting disorders are seven times more frequent. One study showed just a meagre 0.7 per cent benefit for women taking Tamoxifen preventively to reduce the risk of developing further tumours in the breast. HORMONE HERESY - Oestrogen's Deadly Truth -by Sherrill Sellman

I worked for Array Biopharma designing Tamoxifen derivatives for Eli Lilly. Because Tamoxifen was shown to ignite higher cancer rates among women, Eli Lilly hoped to replace it by developing a new "chemical cousin." We were unsuccessful in our attempts. Despite its known danger, Tamoxifen remained on the market. I noticed that ads from Eli Lilly for Tamoxifen insisted that it might decrease cancer risk. This was the exact opposite of what biochemists found in the lab and reported. [2006] Interview of Shane Ellison author of Health Myths Exposed

A 42-year-old woman with metastatic breast cancer developed bilateral optic disc swelling, retinal hemorrhages, and visual impairment three weeks after starting treatment with low doses of tamoxifen. Neurologic evaluation failed to provide an explanation for the ocular findings which resolved completely after cessation of tamoxifen therapy. This case suggests that tamoxifen has the potential for causing serious ophthalmologic toxicity which may be reversible if recognized early.  Tamoxifen citations

A 57-year-old woman developed bilateral optic neuritis after being treated for 6 months with tamoxifen in the dosage of 30 to 40 mg orally a day. As the neuritis progressed during continued treatment and no other causal explanation could be found, tamoxifen was stopped and the optic neuritis regressed. Since tamoxifen might cause optic neuritis the authors recommend the monitoring of ocular symptoms in treated patients Tamoxifen citations

 Specific ocular complications, namely retinopathy, keratopathy and optic neuritis, have been described in women being treated with tamoxifen for metastatic breast cancer or taking this drug as an adjuvant postoperative therapy. We examined 61 patients who had been using tamoxifen for at least one year, in order to detect the incidence of ocular complications. Two patients had retinopathy after having taken high cumulative doses of tamoxifen. Another had corneal deposits and a fourth had optic neuritis. It thus appears that systematic screening of all symptom-free patients using this drug for metastatic breast cancer is superfluous. However, an ophthalmological assessment every two years or earlier in case of visual complaints for patients taking tamoxifen as an adjuvant therapy remains useful, because the oncological therapy can be adjusted if serious ocular complications arise. Tamoxifen citations

Studies show that women taking tamoxifen after surviving breast cancer then have a high propensity to develop endometrial cancer. The NCI and Zeneca Pharmaceuticals, which makes the drug, aggressively lobbied State of California regulators to keep them from adding tamoxifen to their list of carcinogens.  Zeneca is one of the sponsors of Breast Cancer Awareness Month.

That the NCI and ACS have embarked on unethical trials with two hormonal drugs, tamoxifen and Evista, in ill-conceived attempts to prevent breast cancer in healthy women while suppressing evidence that these drugs are known to cause liver and ovarian cancer, respectively, and in spite of the short-term lethal complications of tamoxifen. The establishment also proposes further chemoprevention trials this fall on tamoxifen, and also Evista, in spite of two published long-term European studies on the ineffectiveness of tamoxifen. This represents medical malpractice verging on the criminal. -----Epstein http://www.preventcancer.com/